Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Secukinumab 150 mg Without Load	222
Overall Study	STARTED	Secukinumab 150 mg With Load	220
Overall Study	STARTED	Secukinumab 300 mg With Load	222
Overall Study	STARTED	Placebo	332
Overall Study	COMPLETED	Secukinumab 150 mg Without Load	207
Overall Study	COMPLETED	Secukinumab 150 mg With Load	214
Overall Study	COMPLETED	Secukinumab 300 mg With Load	216
Overall Study	COMPLETED	Placebo	295
Overall Study	NOT COMPLETED	Secukinumab 150 mg Without Load	15
Overall Study	NOT COMPLETED	Secukinumab 150 mg With Load	6
Overall Study	NOT COMPLETED	Secukinumab 300 mg With Load	6
Overall Study	NOT COMPLETED	Placebo	37

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02404350/flow